Optimizing Adjuvant Therapy and Survivorship Care of Stage III Colon Cancer

References

• American Cancer Society . Cancer Facts & Figures 2015. Atlanta, GA, USA (2015).
   Google Scholar
• Böckelman C , EngelmannBE, KaprioT, HansenTF, GlimeliusB. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. Acta Oncol. (Madr.)54(1), 5–16 (2015).
   PubMed Web of Science ®Google Scholar
• André T , De GramontA, VernereyDet al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J. Clin. Oncol.33, 4176–4187 (2015).
   PubMed Web of Science ®Google Scholar
• Moertel CG , FlemingTR, MacdonaldJSet al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann. Intern. Med.122(5), 321–326 (1995).
   PubMed Web of Science ®Google Scholar
• Haller DG , CatalanoPJ, MacdonaldJSet al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J. Clin. Oncol.23(34), 8671–8678 (2005).
   PubMed Web of Science ®Google Scholar
• Efficacy of adjuvant fluorouracil and folinic acid in colon cancer . International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet (London, England)345(8955), 939–944 (1995).
   PubMed Web of Science ®Google Scholar
• Romanina A , LinJT, NiedzwieckiD, BunniM, PriestDGBJ. Role of folypolyglutamates in biochemical modulation of fluorpyrimidines by leucovorin. Cancer Res.51(3), 789–793 (1991).
   PubMed Web of Science ®Google Scholar
• Kuebler JP , WieandHS, O’ConnellMJet al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J. Clin. Oncol.25(16), 2198–2204 (2007).
   PubMed Web of Science ®Google Scholar
• Twelves C , ScheithauerW, MckendrickJet al. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann. Oncol.23(5), 1190–1197 (2011).
   PubMed Web of Science ®Google Scholar
• Schmoll H-J , TaberneroJ, MarounJet al. Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled Phase III trial. J. Clin. Oncol.33(32), 3733–3740 (2015).
   PubMed Web of Science ®Google Scholar
• Pectasides D , KaravasilisV, PapaxoinisGet al. Randomized Phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or. BMC Cancer15(1), 384 (2015).
   PubMedGoogle Scholar
• Schmoll HJ , TwelvesC, SunWet al. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controll. Lancet Oncol.15(13), 1481–1492 (2014).
   PubMed Web of Science ®Google Scholar
• Loree JM , MulderKE, GhoshS, SpratlinJL. CAPOX associated with toxicities of higher grade but improved disease-free survival when compared with FOLFOX in the adjuvant treatment of stage III colon cancer. Clin. Colorectal Cancer13(3), 172–177 (2014).
   PubMed Web of Science ®Google Scholar
• Saltz LB , NiedzwieckiD, HollisDet al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J. Clin. Oncol.25(23), 3456–3461 (2007).
   PubMed Web of Science ®Google Scholar
• Ychou M , RaoulJ-L, DouillardJ-Yet al. A Phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann. Oncol.20(4), 674–680 (2009).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , LabiancaR, BodokyGet al. Randomized Phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J. Clin. Oncol.27(19), 3117–3125 (2009).
   PubMed Web of Science ®Google Scholar
• de Gramont A , Van CutsemE, SchmollH-Jet al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a Phase 3 randomised controlled trial. Lancet. Oncol.13(12), 1225–1233 (2012).
   PubMed Web of Science ®Google Scholar
• Allegra CJ , YothersG, O’ConnellMJet al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J. Clin. Oncol.29(1), 11–16 (2011).
   PubMed Web of Science ®Google Scholar
• Alberts SR , SargentDJ, NairSet al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA307(13), 1383–1393 (2012).
   PubMed Web of Science ®Google Scholar
• Taieb J , TaberneroJ, MiniEet al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised Phase 3 trial. Lancet Oncol.15(8), 862–873 (2014).
   PubMed Web of Science ®Google Scholar
• Taieb J , ZaananA, Le MalicotKet al. Prognostic effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: a post hoc analysis of the PETACC-8 trial. JAMA Oncol.14, 1–11 (2016).
   Google Scholar
• Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J. Clin. Oncol.10(6), 896–903 (1992).
   PubMed Web of Science ®Google Scholar
• Yothers G , O’ConnellMJ, AllegraCJet al. Oxaliplatin as adjuvant therapy for colon cancer: Updated results of NSABP C-07 trial, including survival and subset analyses. J. Clin. Oncol.29(28), 3768–3774 (2011).
   PubMed Web of Science ®Google Scholar
• André T , QuinauxE, LouvetCet al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J. Clin. Oncol.25(24), 3732–3738 (2007).
   PubMed Web of Science ®Google Scholar
• Chau I , NormanAR, CunninghamDet al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann. Oncol.16(4), 549–557 (2005).
   PubMed Web of Science ®Google Scholar
• Kumar A , PeixotoRD, KenneckeHFet al. Effect of adjuvant FOLFOX chemotherapy duration on outcomes of patients with stage III colon cancer. Clin. Colorectal Cancer14(4), 262.e1–268.e1 (2015).
   Web of Science ®Google Scholar
• André T , IvesonT, LabiancaRet al. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) collaboration: prospective combined analysis of Phase III trials investigating duration of adjuvant therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Re. Curr. Colorectal Cancer Rep.9, 261–269 (2013).
   PubMedGoogle Scholar
• Biagi JJ , RaphaelMJ, MackillopWJ, KongW, KingWD, BoothCM. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA305(22), 2335–2342 (2011).
   PubMed Web of Science ®Google Scholar
• Des Guetz G , NicolasP, PerretG-Y, MorereJ-F, UzzanB. Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. Eur. J. Cancer46(6), 1049–1055 (2010).
   PubMed Web of Science ®Google Scholar
• Bos ACRK , van ErningFN, van GestelYRBMet al. Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer. Eur. J. Cancer51(17), 2553–2561 (2015).
   PubMed Web of Science ®Google Scholar
• Peixoto RDA , KumarA, SpeersCet al. Effect of delay in adjuvant oxaliplatin-based chemotherapy for stage III colon cancer. Clin. Colorectal Cancer14(1), 25–30 (2015).
   PubMed Web of Science ®Google Scholar
• Glimelius B , TiretE, CervantesAet al. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol.24(Suppl. 6), vi81–vi88 (2013).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network . Colon Cancer Clinical Practice Guidelines. NCCN Guidelines213–218. www.nccn.org/professionals/physician_gls/f_guidelines.asp.
   Google Scholar
• Yongue G , HotourasA, MurphyJ, MukhtarH, BhanC, ChanCL. The diagnostic yield of preoperative staging computed tomography of the thorax in colorectal cancer patients without hepatic metastases. Eur. J. Gastroenterol. Hepatol.27(4), 467–470 (2015).
   PubMed Web of Science ®Google Scholar
• Hogan J , O’RourkeC, DuffGet al. Preoperative staging CT thorax in patients with colorectal cancer: its clinical importance. Dis. Colon Rectum57(11), 1260–1266 (2014).
   PubMed Web of Science ®Google Scholar
• Kim HY , LeeSJ, LeeGet al. Should preoperative chest CT be recommended to all colon cancer patients? Ann. Surg. 259(2), 323–328 (2014).
   PubMed Web of Science ®Google Scholar
• Nordholm-Carstensen A , Wille-J⊘rgensenPA, JorgensenLN, HarlingH. Indeterminate pulmonary nodules at colorectal cancer staging: a systematic review of predictive parameters for malignancy. Ann. Surg. Oncol.20(12), 4022–4030 (2013).
   PubMed Web of Science ®Google Scholar
• Yancik R , WesleyMN, RiesLAet al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer82(11), 2123–2134 (1998).
   PubMed Web of Science ®Google Scholar
• Sargent DJ , GoldbergRM, JacobsonSDet al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N. Engl. J. Med.345(15), 1091–1097 (2001).
   PubMed Web of Science ®Google Scholar
• Sundararajan V , MitraN, JacobsonJS, GrannVR, HeitjanDF, NeugutAI. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann. Intern. Med.136(5), 349–357 (2002).
   PubMed Web of Science ®Google Scholar
• Ko JJ , KenneckeHF, LimHJet al. Reasons for Underuse of adjuvant chemotherapy in elderly patients with stage III colon cancer. Clin. Colorectal Cancer15(2), 179–185 (2015).
   PubMed Web of Science ®Google Scholar
• Sanoff HK , CarpenterWR, StürmerTet al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J. Clin. Oncol.30(21), 2624–2634 (2012).
   PubMed Web of Science ®Google Scholar
• Tournigand C , AndréT, BonnetainFet al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant tre. J. Clin. Oncol.30(27), 3353–3360 (2012).
   PubMed Web of Science ®Google Scholar
• McCleary NJ , MeyerhardtJA, GreenEet al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J. Clin. Oncol.31(20), 2600–2606 (2013).
   PubMed Web of Science ®Google Scholar
• Haller DG , O’ConnellMJ, CartwrightTHet al. Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. Ann. Oncol.26(4), 715–724 (2015).
   PubMed Web of Science ®Google Scholar
• Sanoff HK , CarpenterWR, MartinCFet al. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J. Natl Cancer Inst.104(3), 211–227 (2012).
   PubMedGoogle Scholar
• Deboever G , HiltropN, CoolM, LambrechtG. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity. Clin. Colorectal Cancer12(1), 8–14 (2013).
   PubMed Web of Science ®Google Scholar
• Saif MW , ShahMM, ShahAR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin. Drug Saf.8(2), 191–202 (2009).
   PubMed Web of Science ®Google Scholar
• Jensen SA , S⊘rensenJB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother. Pharmacol.58(4), 487–493 (2006).
   PubMed Web of Science ®Google Scholar
• Ransom D , WilsonK, FournierMet al. Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. Ann. Oncol.25(1), 117–121 (2014).
   PubMed Web of Science ®Google Scholar
• Cunningham D . Mature results from three large controlled studies with raltitrexed (‘Tomudex’). Br. J. Cancer77(Suppl. 2), 15–21 (1998).
   PubMed Web of Science ®Google Scholar
• Barni S , GhidiniA, CoinuA, BorgonovoK, PetrelliF. A systematic review of raltitrexed-based first-line chemotherapy in advanced colorectal cancer. Anticancer. Drugs25(10), 1122–1128 (2014).
   PubMed Web of Science ®Google Scholar
• Popov I , CarratoA, SobreroAet al. Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: results from the randomised Phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). Eur. J. Cancer44(15), 2204–2211 (2008).
   PubMed Web of Science ®Google Scholar
• Jeffery M , HickeyBE, HiderPN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst. Rev. (1), CD002200 (2007).
   PubMed Web of Science ®Google Scholar
• Tjandra JJ , ChanMKY. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis. Colon Rectum50(11), 1783–1799 (2007).
   PubMed Web of Science ®Google Scholar
• Pita-Fernández S , Alhayek-AíM, González-MartínC, López-CalviñoB, Seoane-PilladoT, Pértega-DíazS. Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis. Ann. Oncol.26(4), 644–656 (2015).
   PubMed Web of Science ®Google Scholar
• Renehan AG , O’DwyerST, WhynesDK. Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer. BMJ328(7431), 81 (2004).
   PubMedGoogle Scholar
• Meyerhardt JA , ManguPB, FlynnPJet al. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American society of clinical oncology clinical practice guideline endorsement. J. Clin. Oncol.31(35), 4465–4470 (2013).
   PubMed Web of Science ®Google Scholar
• Shah MA , RenfroLA, AllegraCJet al. Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer: analysis from modern-era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. J. Clin. Oncol.34(8), 843–853 (2016).
   PubMed Web of Science ®Google Scholar
• Verberne CJ , ZhanZ, van den HeuvelEet al. Intensified follow-up in colorectal cancer patients using frequent Carcino-Embryonic Antigen (CEA) measurements and CEA-triggered imaging: results of the randomized “CEAwatch” trial. Eur. J. Surg. Oncol.41(9), 1188–1196 (2015).
   PubMed Web of Science ®Google Scholar
• Primrose JN , PereraR, GrayAet al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA311(3), 263–270 (2014).
   PubMed Web of Science ®Google Scholar
• Lee-Ying RM , RenoufDJ, LimHJet al. Utility of surveillance following curative intent resection of metastases. ASCO Meet. Abstr.33(Suppl. 15), 6562 (2015).
   Google Scholar
• Wang Y , ChenL, RuanJY, CheungWY. Discussions about reproductive and sexual health among young adult survivors of cancer. Cancer Med. doi: 10.1002/cam4.666 (2016) ( Epub ahead of print).
   Google Scholar
• Bines J , OleskeDM, CobleighMA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J. Clin. Oncol.14(5), 1718–1729 (1996).
   PubMed Web of Science ®Google Scholar
• D’Souza UJA . Toxic effects of 5-Fluorouracil on sperm count in wistar rats. Malays. J. Med. Sci.10(1), 43–45 (2003).
   PubMedGoogle Scholar
• Choudhury RC , MisraS, JagdaleMB, PaloAK. Induction and transmission of cytogenetic toxic effects of 5-fluorouracil in male germline cells of Swiss mice. J. Exp. Clin. Cancer Res.21(2), 277–282 (2002).
   PubMed Web of Science ®Google Scholar
• Cercek A , SiegelCL, CapanuM, Reidy-LagunesD, SaltzLB. Incidence of chemotherapy-induced amenorrhea in premenopausal women treated with adjuvant FOLFOX for colorectal cancer. Clin. Colorectal Cancer12(3), 163–167 (2013).
   PubMed Web of Science ®Google Scholar
• Levi M , ShalgiR, BrennerBet al. The impact of oxaliplatin on the gonads: from bedside to the bench. Mol. Hum. Reprod.21(12), 885–893 (2015).
   PubMed Web of Science ®Google Scholar
• Skaznik-Wikiel ME , GilbertSB, MeachamRB, KondapalliLA. Fertility preservation options for men and women with cancer. Rev. Urol.17(4), 211–219 (2015).
   PubMedGoogle Scholar
• Shen Y-W , ZhangX-M, LvMet al. Utility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and meta-analysis. Onco. Targets. Ther.8, 3349–3359 (2015).
   PubMed Web of Science ®Google Scholar
• Munhoz RR , PereiraAAL, SasseADet al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis. JAMA Oncol.2(1), 65–73 (2016).
   PubMed Web of Science ®Google Scholar
• Pachman DR , QinR, SeislerDKet al. Clinical course of oxaliplatin-induced neuropathy: results from the randomized Phase III trial N08CB (alliance). J. Clin. Oncol.33(30), 3416–3422 (2015).
   PubMed Web of Science ®Google Scholar
• Kidwell K , YothersG, GanzPet al. Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from NSABP trials C-07 and LTS-01. 118(22), 5614–5622 (2012).
   Google Scholar
• Loprinzi CL , QinR, DakhilSRet al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J. Clin. Oncol.32(10), 997–1005 (2014).
   PubMed Web of Science ®Google Scholar
• Zimmerman C , AthertonPJ, PachmanDet al. MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. Support. Care Cancer24(3), 1071–1078 (2016).
   PubMed Web of Science ®Google Scholar
• Guo Y , JonesD, PalmerJLet al. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Support. Care Cancer22(5), 1223–1231 (2014).
   PubMed Web of Science ®Google Scholar
• Salehi Z , RoayaeiM. Effect of vitamin E on oxaliplatin-induced peripheral neuropathy prevention: a randomized controlled trial. Int. J. Prev. Med.6, 104 (2015).
   PubMed Web of Science ®Google Scholar
• Balayssac D , FerrierJ, PereiraBet al. Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial. BMJ Open5(4), e007479 (2015).
   PubMed Web of Science ®Google Scholar
• Smith EML , PangH, CirrincioneCet al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA309(13), 1359–1367 (2013).
   PubMed Web of Science ®Google Scholar
• Majithia N , TemkinSM, RuddyKJ, BeutlerAS, HershmanDL, LoprinziCL. National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons. Support. Care Cancer24(3), 1439–1447 (2015).
   PubMed Web of Science ®Google Scholar
• Meyerhardt J a , HeseltineD, NiedzwieckiDet al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J. Clin. Oncol.24(22), 3535–3541 (2006).
   PubMed Web of Science ®Google Scholar
• Jeon J , SatoK, NiedzwieckiDet al. Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: findings from CALGB 89803/Alliance. Clin. Colorectal Cancer12(4), 233–238 (2013).
   PubMed Web of Science ®Google Scholar
• Campbell PT , PatelA V, NewtonCC, JacobsEJ, GapsturSM. Associations of recreational physical activity and leisure time spent sitting with colorectal cancer survival. J. Clin. Oncol.31(7), 876–885 (2013).
   PubMed Web of Science ®Google Scholar
• van Waart H , StuiverMM, van HartenWHet al. Effect of low-intensity physical activity and moderate- to high-intensity physical exercise during adjuvant chemotherapy on physical fitness, fatigue, and chemotherapy completion rates: results of the PACES randomized clinical trial. J. Clin. Oncol.33(17), 1918–1927 (2015).
   PubMed Web of Science ®Google Scholar
• Sinicrope FA , FosterNR, YothersGet al. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer119(8), 1528–1536 (2013).
   PubMed Web of Science ®Google Scholar
• Dignam JJ , PoliteBN, YothersGet al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J. Natl Cancer Inst.98(22), 1647–1654 (2006).
   PubMed Web of Science ®Google Scholar
• Campbell PT , NewtonCC, DehalAN, JacobsEJ, PatelA V, GapsturSM. Impact of body mass index on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J. Clin. Oncol.30(1), 42–52 (2012).
   PubMed Web of Science ®Google Scholar
• Meyerhardt J a , NiedzwieckiD, HollisDet al. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J. Clin. Oncol.26(25), 4109–4115 (2008).
   PubMed Web of Science ®Google Scholar
• Ng K , OginoS, MeyerhardtJAet al. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J. Natl Cancer Inst.103(20), 1540–1551 (2011).
   PubMed Web of Science ®Google Scholar
• Cai H , ZhangG, WangZ, LuoZ, ZhouX. Relationship between the use of statins and patient survival in colorectal cancer: a systematic review and meta-analysis. PLoS ONE10(6), e0126944 (2015).
   PubMed Web of Science ®Google Scholar
• Maalmi H , Ordóñez-MenaJM, SchöttkerB, BrennerH. Serum 25-hydroxyvitamin D levels and survival in colorectal and breast cancer patients: systematic review and meta-analysis of prospective cohort studies. Eur. J. Cancer50(8), 1510–1521 (2014).
   PubMed Web of Science ®Google Scholar
• Baron JA , BarryEL, MottLAet al. A trial of calcium and vitamin D for the prevention of colorectal adenomas. N. Engl. J. Med.373(16), 1519–1530 (2015).
   PubMed Web of Science ®Google Scholar
• Fransgaard T , ThygesenLC, GögenurI. Metformin increases overall survival in patients with diabetes undergoing surgery for colorectal cancer. Ann. Surg. Oncol.; 23(5), 1569–1575 (2015).
   PubMed Web of Science ®Google Scholar
• Dubé C . The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. preventive services task force. Ann. Intern. Med.146(5), 365 (2007).
   PubMed Web of Science ®Google Scholar
• Bains S , MahicM, CvancarovaMet al. Impact of aspirin as secondary prevention in an unselected cohort of 25,644 patients with colorectal cancer: a population-based study. J. Clin. Oncol.33(Suppl.), Abstract 3504 (2015).
   Google Scholar
• Baron JA , SandlerRS, BresalierRSet al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology131(6), 1674–1682 (2006).
   PubMed Web of Science ®Google Scholar
• Midgley RS , McConkeyCC, JohnstoneECet al. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J. Clin. Oncol.28(30), 4575–4580 (2010).
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery – ClinicalTrials.gov, NCT01150045 (2016). https://clinicaltrials.gov/ct2/show/NCT01150045.
   Google Scholar
• Muir P , LiS, LouSet al. The real cost of sequencing: scaling computation to keep pace with data generation. Genome Biol.17(1), 53 (2016).
   PubMed Web of Science ®Google Scholar
• Guinney J , DienstmannR, WangXet al. The consensus molecular subtypes of colorectal cancer. Nat. Med.21(11), 1350–1356 (2015).
   PubMed Web of Science ®Google Scholar
• Le Tourneau C , DelordJ-P, GonçalvesAet al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled Phase 2 trial. Lancet Oncol.16, 1–11 (2015).
   PubMed Web of Science ®Google Scholar
• Melero JT , OrtegaFG, GonzalezAMet al. Prognostic factor analysis of circulating tumor cells in peripheral blood of patients with peritoneal carcinomatosis of colon cancer origin treated with cytoreductive surgery plus an intraoperative hyperthermic intraperitoneal chemotherapy procedure (CRS + HIPEC). Surgery159(3), 728–735 (2016).
   PubMed Web of Science ®Google Scholar
• Satelli A , MitraA, BrownleeZet al. Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin. Cancer Res.21(4), 899–906 (2015).
   PubMed Web of Science ®Google Scholar
• Bork U , RahbariNN, SchölchSet al. Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study. Br. J. Cancer112(8), 1306–1313 (2015).
   PubMed Web of Science ®Google Scholar
• Reinert T , Sch⊘lerL V, ThomsenRet al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut65(4), 625–634 (2015).
   PubMed Web of Science ®Google Scholar